HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kanabo Studying Vaping With CBD And Nicotine Mix To Help Smokers Quit Tobacco And Nicotine

Executive Summary

Kanabo, with headquarters in London and R&D in Tel Aviv, says its CBD and nicotine formula has advanced in the patent process from being recognized in the UK to being considered for recognition in the US and the EU, a step it calls “the last phase before becoming an internationally approved patent.”

You may also be interested in...



Will Novel NRT Interest Heat Up In US With First Clearance For ENDS Under Tobacco Control Act?

Without mentioning NRT space, FDA’s acceptance of one vape device and two replacement nicotine cartridges as tobacco products might reignite interest in proposals for ENDS or other novel products to be approved for smoking cessation claims. To gain clearance as tobacco products, the ENDS were shown to provide a benefit similar to efficacies required for an NRT.

J&J’s Nicorette QuickMist SmartTrack – Getting Inside One Of 2020’s Biggest UK Launches

HBW Insight speaks to Johnson & Johnson's Bill Twomey and Sven Sjovall about how one of the biggest OTC launches of 2020 – Nicorette QuickMist SmartTrack – uses behavioral science techniques to help motivate consumers to quit smoking and overcame COVID-related supply chain difficulties to launch a much-needed digital smoking cessation aid in the middle of a pandemic. 

GSK’s Proposal For Mouth Spray Nicorette Delayed By FDA Questions On Label

Glaxo plans to make changes FDA requested in Complete Response letter sent on 18 October, the agency’s deadline for acting on NDA for an oral spray that delivers 1 mg per spray of aqueous buffered nicotine solution for oromucosal use.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel